These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30955188)

  • 21. Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis.
    Mei C; Chen N; Ding X; Yu X; Wang L; Qian J; Wang M; Jiang G; Li X; Hou F; Zuo L; Wang N; Liu H
    Hemodial Int; 2016 Oct; 20(4):589-600. PubMed ID: 26940692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients.
    Koiwa F; Tokunaga S; Asada S; Endo Y; Fukagawa M; Akizawa T
    Kidney Int Rep; 2021 Nov; 6(11):2830-2839. PubMed ID: 34805635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study.
    Takeuchi Y; Nishida Y; Kondo Y; Imanishi Y; Fukumoto S
    J Bone Miner Metab; 2020 Sep; 38(5):687-694. PubMed ID: 32274572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
    Ketteler M; Martin KJ; Cozzolino M; Goldsmith D; Sharma A; Khan S; Dumas E; Amdahl M; Marx S; Audhya P
    Nephrol Dial Transplant; 2012 May; 27(5):1942-9. PubMed ID: 21931122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients.
    Fukagawa M; Yokoyama K; Shigematsu T; Akiba T; Fujii A; Kuramoto T; Odani M; Akizawa T;
    Nephrol Dial Transplant; 2017 Oct; 32(10):1723-1730. PubMed ID: 28057872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism, improve arterial stiffness in patients on continuous ambulatory peritoneal dialysis?
    Suzuki H; Inoue T; Watanabe Y; Kikuta T; Sato T; Tsuda M; Uchida K
    Adv Perit Dial; 2011; 27():134-9. PubMed ID: 22073845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The influence of side effects related to cinacalcet therapy on compliance in hemodialysis patients suffering from secondary hyperparathyroidism].
    Zwiech R; Chrul S
    Wiad Lek; 2012; 65(3):145-50. PubMed ID: 23289260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2MD (DP001), a Single Agent in the Management of Hemodialysis Patients: A Randomized Trial.
    Thadhani R; Zella JB; Knutson DC; Blaser WJ; Plum LA; Clagett-Dame M; Buck RD; DeLuca HF
    Am J Nephrol; 2017; 45(1):40-48. PubMed ID: 27880946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.
    Frazão JM; Messa P; Mellotte GJ; Geiger H; Hagen EC; Quarles LD; Kerr PG; Baños A; Dehmel B; Urena P
    Clin Nephrol; 2011 Sep; 76(3):233-43. PubMed ID: 21888861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.
    Akizawa T; Shimazaki R; Shiramoto M; Fukagawa M;
    Clin Drug Investig; 2018 Oct; 38(10):945-954. PubMed ID: 30168004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH].
    Zwiech R; Dryja P; Łacina D; Nykiel P; Sek-Szczepanowska K; Bratkowska K; Pietrzak B; Chrul S
    Wiad Lek; 2011; 64(4):267-73. PubMed ID: 22533150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akiba T; Akizawa T; Tsukamoto Y; Uchida E; Iwasaki M; Koshikawa S;
    Ther Apher Dial; 2008 Apr; 12(2):117-25. PubMed ID: 18387159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
    Warady BA; Iles JN; Ariceta G; Dehmel B; Hidalgo G; Jiang X; Laskin B; Shahinfar S; Vande Walle J; Schaefer F
    Pediatr Nephrol; 2019 Mar; 34(3):475-486. PubMed ID: 30506144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
    Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
    Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
    Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
    J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.